Phaseline

Companies › LTZ Therapeutics

LTZ Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Feb 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
LTZ-301
unclear - specific target not disclosed in trial registry
–Phase 1Non-Hodgkin Lymphoma Refractory/ RelapsedFeb 2028
LTZ-232–Phase 1Colorectal CancerDec 2031

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07121946LTZ-301Phase 1Non-Hodgkin Lymphoma Refractory/ RelapsedOncologyFeb 2028
NCT07878988LTZ-232Phase 1Colorectal CancerOncologyDec 2031

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.